PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
ProQR Therapeutics N.V.
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026
$1.31+0.00 (0.00%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Operating margin
-273.1%
Net margin
-265.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -15.9% | +64.2% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -61.5% | -61.2% | |
| Return on assets | – | -43.1% | -30.1% | |
| Current ratio | 9.24 | 7.77 | 3.09 | |
| Debt to equity | 0.11 | 0.32 | – | |
| Net debt to EBITDA | 1.40× | 1.43× | – | |
| Interest coverage | – | -10.5× | -33.8× | |
| Capex to revenue | – | – | 6.4% | |
| Diluted shares | 23M | 50M | 105M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ProQR Therapeutics generated €205.25M from operations and spent €5.00M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€205.25M
Used
€5.00M
Capital expenditure€5.00M100%Dividends€00%Share buybacks€00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-265.2%
×Asset turnover0.11×
×Equity multiplier2.04×
=Return on equity, FY2025-61.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -265.2% | 0.11× | 2.04× | -61.2% |
| FY2024 | -146.9% | 0.12× | 2.35× | -42.7% |
| FY2023 | -431.7% | 0.04× | 2.85× | -51.9% |
| FY2022 | -1792.5% | 0.02× | 2.11× | -71.2% |
| FY2021 | -4549.8% | 0.01× | 1.80× | -71.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-€42.18M
- Cash generatingOperating cash flow above zero-€52.79M
- Return on assets improvedROA up on the prior year-20.1% → -25.1%
- Earnings backed by cashOperating cash flow above net income-€52.79M vs -€42.18M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.95 → 3.09
- No dilutionShare count did not rise86M → 105M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.14 → 0.09